Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Contact Dermatitis ; 90(2): 161-168, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37960922

RESUMEN

BACKGROUND: Overall adherence in the treatment of chronic dermatoses is poor. Textbooks state an adherence dependence on galenics. TRIAL DESIGN: Prospective, randomized, parallel-grouped, single-blinded (investigator), monocentric clinical trial (phase IV) on the adherence to treatment of chronic mild to moderate hand eczema with topical methylprednisolone aceponate (MPA, Advantan®) in different vehicles. OBJECTIVES AND ENDPOINTS: Primary objective was the assessment of the adherence depending on vehicle type in patients with chronic hand eczema. Secondary objective was improvement after a 4-week treatment period. Primary Endpoint Adherence is defined as the percentage of patients applying at least aimed daily dose. Prescribed daily dose was defined as the planned number of applications per day (1) * surface (measured) * aimed amount per application (mg/cm2 ). Truly applicated daily dose was evaluated as individual mean amount per dose * individual mean number of applications per day. Adherence was assumed, if truly applicated daily dose is at least 75% of the prescribed daily dose and the individual mean number of applications per day is at least 0.85. Secondary Endpoint Efficacy was measured by improvement of Hand Eczema Severity Index (HECSI) and Investigator's Global Assessment (IGA) after a 4-week treatment period and in addition to Quality of Life in Hand Eczema Questionnaire (QOLHEQ) and Visual Analogue Scale (VAS) to assess pruritus. METHODS: Number of participants randomized to each group 40, 80 total. Group 1 MPA-C: Methylprednisolone aceponate 0.1% cream and barrier repair emollient (Bepanthen® Sensiderm). Group 2 MPA-FO: Methylprednisolone aceponate 0.1% fatty ointment and barrier repair emollient (Bepanthen® Sensiderm). Adherence to treatment was compared via Fisher's exact test. RESULTS: Of the patients, 48% were adherent according to our definition. There was no significant difference between MPA-C (42.1%) and MPA-FO (54.1%; p = 0.36; group difference-12.0%, 95% CI-34.3%-11.5%). Generalized-linear-model-analysis of adherence to study treatment with factors emollient use, treatment, time and treatment-time interaction showed a parallel between adherence and amount of emollient use (odds ratio 1.74, p = 0.0038; 95% CI-1.22-2.52). Improvement of hand eczema was seen according to clinical scores without remarkable differences between the groups. CONCLUSIONS: No dependence of adherence on galenics of topical treatment of chronic hand eczema could be proved. Patients who use more emollient tend to be more adherent to the topical treatment.


Asunto(s)
Dermatitis Alérgica por Contacto , Eccema , Ácido Pantoténico/análogos & derivados , Humanos , Emolientes/uso terapéutico , Pomadas , Calidad de Vida , Estudios Prospectivos , Dermatitis Alérgica por Contacto/tratamiento farmacológico , Metilprednisolona , Eccema/tratamiento farmacológico , Eccema/inducido químicamente , Resultado del Tratamiento
2.
Dermatopathology (Basel) ; 11(1): 19-25, 2023 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-38247726

RESUMEN

Folliculosebaceous cystic hamartoma (FSCH) is a rare and benign form of cutaneous hamartomas. These skin lesions often lead to clinical and histopathological misdiagnosis due to their similarities to cutaneous lesions with overproduction of clustered sebaceous glands. Clinically, the lesions often present as solitary, skin-colored, pedunculated warts to cauliflower-like, exophytic papules and nodules, usually with a diameter ranging 0.5-1.5 cm that rarely exceed 2 cm in size. Only a small number of giant variants are reported in the literature with a diameter in the range of 5-23 cm. The vast majority of the lesions appear in the central face and show a striking predilection for the nose, ears, and scalp, but also emerge on the nipples, extremities, and genitals. Histologically, the epithelial components of folliculosebaceous cystic hamartoma comprise dilated infundibular cystic proliferation with surrounding mesenchymal components, which commonly include fibroplasia and vascular and adipose tissue proliferation. These histological characteristics were coined by Kimura and colleagues (1991). To the best of our knowledge, our case represents the biggest variant of giant folliculosebaceous cystic hamartoma.

6.
Hautarzt ; 71(11): 899-902, 2020 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-32720167

RESUMEN

Ringworm in cattle may cause an occupational skin disease in humans. Trichophyton verrucosum lead to a highly inflammatory fungal skin infection that is often misdiagnosed as bacterial disease and consequently mistreated with antibiotics. To establish the correct diagnosis, it is necessary to collect skin scales; in addition, a skin biopsy can be helpful. Deep dermatophyte infections by Trichophyton verrucosum can be treated effectively with oral terbinafine. In addition, it is necessary to pay careful attention to use suitable hygiene measures in the stables to protect against reinfection.


Asunto(s)
Tiña , Trichophyton , Animales , Bovinos , Agricultores , Humanos , Piel , Terbinafina , Tiña/diagnóstico , Tiña/tratamiento farmacológico
8.
J Dtsch Dermatol Ges ; 17(10): 1039-1052, 2019 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-31631543
9.
J Dtsch Dermatol Ges ; 17(10): 1039-1051, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31562692

RESUMEN

Eosinophilic dermatoses are a heterogeneous group of diseases, characterized by an eosinophil-rich infiltrate and/or degranulation of eosinophils. Blood eosinophilia may be an associated feature. Typical, albeit not specific histological findings include 'flame figures', which are caused by the accumulation of cationic proteins released by eosinophils and subsequent collagen denaturation. "Classic" eosinophilic dermatoses include eosinophilic cellulitis (Wells syndrome), granuloma faciale, eosinophilic fasciitis (Shulman syndrome) and eosinophilic folliculitis (Ofuji disease). In addition, there is a multitude of skin diseases that present with varying degrees of eosinophilic infiltration. These include atopic dermatitis, bullous pemphigoid, urticaria, allergic contact dermatitis, prurigo nodularis, arthropod bite reaction, parasitic infections, and drug hypersensitivity. Even though these disorders share a common characteristic (tissue eosinophilia), they differ greatly in their clinical presentation.


Asunto(s)
Colágeno/metabolismo , Proteína Catiónica del Eosinófilo/metabolismo , Eosinófilos/inmunología , Enfermedades de la Piel/inmunología , Celulitis (Flemón)/tratamiento farmacológico , Celulitis (Flemón)/inmunología , Celulitis (Flemón)/patología , Dermatitis Alérgica por Contacto/tratamiento farmacológico , Dermatitis Alérgica por Contacto/inmunología , Dermatitis Alérgica por Contacto/patología , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/inmunología , Dermatitis Atópica/patología , Hipersensibilidad a las Drogas/tratamiento farmacológico , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/patología , Eosinofilia/tratamiento farmacológico , Eosinofilia/inmunología , Eosinofilia/patología , Eosinófilos/patología , Eosinófilos/ultraestructura , Fascitis/tratamiento farmacológico , Fascitis/inmunología , Fascitis/patología , Foliculitis/tratamiento farmacológico , Foliculitis/inmunología , Foliculitis/patología , Granuloma/tratamiento farmacológico , Granuloma/inmunología , Granuloma/patología , Humanos , Mordeduras y Picaduras de Insectos/tratamiento farmacológico , Mordeduras y Picaduras de Insectos/inmunología , Mordeduras y Picaduras de Insectos/patología , Enfermedades Parasitarias/tratamiento farmacológico , Enfermedades Parasitarias/inmunología , Enfermedades Parasitarias/patología , Penfigoide Ampolloso/tratamiento farmacológico , Penfigoide Ampolloso/inmunología , Penfigoide Ampolloso/patología , Prurigo/tratamiento farmacológico , Prurigo/inmunología , Prurigo/patología , Enfermedades de la Piel/clasificación , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/patología , Enfermedades Cutáneas Vesiculoampollosas/tratamiento farmacológico , Enfermedades Cutáneas Vesiculoampollosas/inmunología , Enfermedades Cutáneas Vesiculoampollosas/patología , Urticaria/tratamiento farmacológico , Urticaria/inmunología , Urticaria/patología
11.
J Dtsch Dermatol Ges ; 16(5): 560-566, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29750441
12.
J Dtsch Dermatol Ges ; 16(5): 559-564, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29689138

RESUMEN

BACKGROUND: Dermatitis artefacta is a relevant and frequently unrecognized clinical condition associated with self-harming behavior, in which unconscious manipulation causes skin lesions. While atypical lesions and an unusual disease course may give rise to clinical suspicion of a self-induced disorder, questioning and examining these patients usually fails to confirm or clarify this suspicion. In this setting, the dermatopathologist may be faced with the question whether there are any histological signs corroborating the diagnosis of dermatitis artefacta. METHODS: We conducted a Pubmed search (without time frame) using the terms "dermatitis artefacta", "factitious/factitial dermatitis", "artefactual skin" in combination with "histology" or "pathology". Given the low number of hits, we extended the search by adding terms related to certain types of injuries (for example, "burn" or "cold") in order to identify specific patterns. RESULTS: In general, there are only few studies investigating the histological features of factitious skin disorders. Another problem arises from the fact that, even if clinical and histological findings are suggestive of dermatitis artefacta, subsequent confirmation of the exact mechanism of injury is frequently not possible, thus leaving room for speculation. This complicates defining specific histological patterns based on the various types of injuries. Overall, the results of the present study suggest that a factitious disorder should be considered if histological findings include blistering with a mild inflammatory infiltrate, rupture of collagen fibers, multinucleated keratinocytes, or elongated and vertically aligned keratinocytic nuclei.


Asunto(s)
Dermatitis , Trastornos Fingidos , Dermatitis/diagnóstico , Dermatitis/patología , Diagnóstico Diferencial , Trastornos Fingidos/diagnóstico , Trastornos Fingidos/patología , Humanos , Queratinocitos , Conducta Autodestructiva
14.
Acta Derm Venereol ; 98(3): 310-317, 2018 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-29136262

RESUMEN

Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process. CPL may appear as localized or disseminated skin lesions. While most cases of CPL are idiopathic, they may also occur as a response to, for example, contact dermatitis, arthropod reactions, and bacterial infections. CPL can be classified based on its clinical features, but all variants have similar histopathological patterns of either predominantly B-cell infiltrates, T-cell infiltrates, or mixed T/B-cell infiltrates. The prognosis of CPL is good, but the underlying disease process should be taken into account. If an antigenic stimulus is identified, it should be removed. In patients with idiopathic CPL, a close follow-up control strategy should be adopted. The aim of this systematic review is to summarize all reported treatments for CPL. The review was based on articles from the PubMed database, using the query "skin pseudolymphoma treatment", English and German, about "human" subjects, and published between 1990 and 2015 documenting adequate treatment and/or aetiology. Mainly individual case reports and small case series were found. Treatment options include topical and intralesional agents, systemic agents, and physical modalities. The final part of the review proposes a treatment algorithm for CPL according to each aetiology, based on the literature of the last 25 years. Future research should focus on randomized controlled trials and studies on long-term outcomes, which were not identified in the current review.


Asunto(s)
Linfocitos B/efectos de los fármacos , Fármacos Dermatológicos/uso terapéutico , Procedimientos Quirúrgicos Dermatologicos , Seudolinfoma/terapia , Enfermedades de la Piel/terapia , Piel/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos B/inmunología , Fármacos Dermatológicos/efectos adversos , Procedimientos Quirúrgicos Dermatologicos/efectos adversos , Humanos , Valor Predictivo de las Pruebas , Seudolinfoma/diagnóstico , Seudolinfoma/etiología , Seudolinfoma/inmunología , Factores de Riesgo , Piel/inmunología , Piel/patología , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/etiología , Enfermedades de la Piel/inmunología , Linfocitos T/inmunología , Resultado del Tratamiento
16.
J Dtsch Dermatol Ges ; 15(2): 151-158, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28214306

RESUMEN

Die Necrobiosis lipoidica ist eine seltene granulomatöse Erkrankung von bisher unzureichend geklärter Ätiologie. Häufig stellt die bei Diabetikern gehäuft zu beobachtende und zur Ulzeration neigende Dermatose eine starke Belastung für die Patienten dar. Bezüglich der Therapie existieren aktuell keine deutschen oder europäischen Leitlinien. Gleichzeitig lässt sich unter der aktuellen Standardtherapie, der lokalen oder intraläsionalen Anwendung von Glukokortikoiden, nicht immer ein zufriedenstellendes Ansprechen beobachten. Daher wurde untersucht, ob seit dem Jahr 2000 publizierte Therapiemodalitäten das Therapiespektrum relevant und erfolgversprechend erweitern. Es erfolgte eine Betrachtung aller Arbeiten im oben genannten Zeitraum, bei denen mehr als ein Einzelfallbericht je Therapiemodalität publiziert wurde. Insgesamt wurden in einem systematischen Review die Daten von 16 verschiedenen, seit 2000 publizierten Therapieverfahren in 49 Publikationen analysiert. Im Ergebnis zeigte sich, dass die meisten Erfahrungen bezüglich der topischen PUVA-Therapie, der photodynamischen Therapie (PDT) und der systemischen Therapie mit Fumarsäureestern vorliegen. Allerdings ist auffällig, dass mit steigender Zahl der pro Behandlungsmodalität behandelten Patienten der Anteil der Patienten, bei denen eine Abheilung bzw. eine teilweise Abheilung berichtet wurde, sinkt. Wir interpretieren diese Beobachtung als Publikationsbias. Daher kann für keines der besprochenen Verfahren eine klare Empfehlung als Therapie der zweiten Wahl nach Versagen der lokalen bzw. intraläsionalen Steroidtherapie gegeben werden.

17.
J Dtsch Dermatol Ges ; 15(2): 151-157, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28214312

RESUMEN

Necrobiosis lipoidica (NL) is a rare granulomatous disease of hitherto unclear etiology frequently seen in patients with diabetes. Characterized by its potential for ulcerations, it often presents a serious burden for those affected. There are currently neither German nor European guidelines for the treatment of NL. At the same time, standard treatment with topical or intralesional corticosteroids does not always show satisfactory results. We therefore set out to evaluate whether the various treatment regimens published since 2000 have actually expanded the therapeutic armamentarium in a relevant manner. Included were all publications that described more than one patient being treated with any given therapeutic modality. Overall, we analyzed data for 16 different treatment regimens reported in 49 publications. The largest amount of data exists for topical PUVA therapy, photodynamic therapy (PDT), and systemic treatment with fumaric acid esters. Remarkably, our analysis showed that with an increase in the number of documented patients treated with a given therapeutic modality, the proportion of those achieving a complete or partial response actually decreased. This was interpreted as publication bias. Thus, no clear recommendation can be given for second-line therapy in case topical or intralesional corticosteroids fail.


Asunto(s)
Corticoesteroides/administración & dosificación , Fumaratos/administración & dosificación , Necrobiosis Lipoidea/diagnóstico , Necrobiosis Lipoidea/terapia , Terapia PUVA/métodos , Fotoquimioterapia/métodos , Administración Cutánea , Terapia Combinada , Medicina Basada en la Evidencia , Humanos , Resultado del Tratamiento
19.
Am J Dermatopathol ; 37(2): e15-7, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25238447

RESUMEN

Eosinophilic cellulitis is an inflammation of, until now, unknown etiology that was first described by George Wells in 1971. Its dominating histological hallmarks are so-called "flame figures" and an eosinophilic infiltrate. Here, we report the case of a 46-year-old man who initially presented with excoriated papules that were histologically interpreted as consistent with "arthropod reactions." Later on, the clinical presentation changed to erythematous plaques, partially with cockade-like aspects. At this time, new biopsies were performed showing a superficial and deep perivascular lymphocytic and heavily eosinophilic infiltrate and flame figures, thus allowing to establish the diagnosis of Wells' syndrome. Under treatment with oral prednisolone and dapsone, the patient showed a rapid improvement of the condition. The presented case demonstrates both the clinical and histopathologic life of lesions of Well's syndrome in the course of the disease from unspecific to distinctive. The need for repeated biopsies is discussed. Current understanding of the pathogenesis of Wells' syndrome and its correlating histological features are elucidated.


Asunto(s)
Celulitis (Flemón)/diagnóstico , Errores Diagnósticos , Eosinofilia/diagnóstico , Piel/patología , Administración Oral , Antipruriginosos/uso terapéutico , Biopsia , Celulitis (Flemón)/tratamiento farmacológico , Celulitis (Flemón)/patología , Dapsona/administración & dosificación , Dimetindeno/administración & dosificación , Quimioterapia Combinada , Eosinofilia/tratamiento farmacológico , Eosinofilia/patología , Glucocorticoides/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Prednisolona/administración & dosificación , Piel/efectos de los fármacos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA